Hepatitis C Direct Acting Antiviral Treatment Interruptions | June 7, 2023
Date of Presentation: June 7, 2023
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #daa #direct acting antiviral #hcv #missed doses #treatment interruption
In this presentation Dr. Karla Thornton discusses how to apply the guidance provided by the AASLD/IDSA on HCV DAA treatment interruptions, identify when patients should have DAA therapy continued vs when DAA therapy should be stopped, and also describes the data in patients with incomplete adherence.
Recording:
Presented by:
Dr. Karla Thornton, MD, MPH
Karla Thornton, MD, MPH is a Professor in the Division of Infectious Diseases at the University of New Mexico School of Medicine in Albuquerque, New Mexico and currently serves as a Senior Associate Director of Project ECHO (Extension for Community Healthcare Outcomes). Her clinical expertise is in the treatment of viral hepatitis and she oversees all of the Viral Hepatitis Programs run out of the ECHO Institute including the Community, Corrections and Indian Country HCV TeleECHO programs. Through these programs, she trains primary care providers and their teams how to comprehensively care for patients with chronic HCV. In addition, she started the New Mexico Peer Education Project: Prisoner Health is Community Health in 2009, which trains New Mexico state prisoners to be peer educators and experts in HCV, other infectious diseases and addiction. She currently serves as the co-chair of the World Health Organization’s Guidelines Development Group for the treatment of persons with hepatitis C virus infection.
Resources Provided:
Date added: June 5, 2023